Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 15, 2026
short_interest_report
Short Interest: OSPN up 6% to 4.0M shares
Settlement 2026-09-15 | Days to cover: 10.03 | ≈10.75% of shares outstanding (est.)
Aug 31, 2026
short_interest_report
Short Interest: OSPN up 7% to 3.7M shares
Settlement 2026-08-31 | Days to cover: 10.33 | ≈10.13% of shares outstanding (est.)
Aug 4, 2026
earnings_calendar
OSPN Q2 2026 Earnings Scheduled — 2026-08-04
Apr 30, 2026
earnings_calendar
OSPN Q1 2026 Earnings Scheduled — 2026-04-30
Feb 26, 2026
earnings_calendar
OSPN Q4 2025 Earnings After Market Close — 2026-02-26
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
Period
EPS Est.
Range
Growth
30d Rev
Up/Dn
Revenue
#
Current Q
$0.24
$0.21–$0.26
-28.5%
-18.6%
0↑3↓
$0.1B
5
Next Q
$0.32
$0.28–$0.34
-12.2%
+0.6%
1↑2↓
$0.1B
5
Current FY
$1.24
$1.22–$1.27
-16.5%
+2.3%
4↑0↓
$0.3B
5
Next FY
$1.30
$1.21–$1.37
4.8%
-0.6%
3↑0↓
$0.3B
5
Current-quarter EPS estimate — revision history
When
EPS estimate
Change vs now
Current
$0.236
—
7d ago
$0.290
-0.054
30d ago
$0.290
-0.054
60d ago
$0.290
-0.054
90d ago
$0.290
-0.054
Institutional ownership
Which big funds own OSPN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $402.1M total value (28,066,955 shares) as of 2026-Q2. Top holders: BlackRock,, Legal, Neuberger. Net buying activity: 23 institutions added/increased vs 10 reduced.